Many employees at the Food and Drug Administration (FDA) were shocked this week when they found out they had lost their jobs. On Tuesday morning, around 3,500 staff members were let go, and some learned they were fired only when their badge access failed as they tried to enter the building.
The layoffs affected various departments within the FDA, particularly those focused on food, drug, and medical device policies. Senior leaders were also removed from their positions, leading to a major shake-up within the agency. Brian King, who led the tobacco regulation division, was offered a new role with a regional office of the Indian Health Service that includes Alaska. His predecessor, Mitch Zeller, confirmed this transition.
The cuts also impacted teams responsible for overseeing veterinary medicine and those who handle the extensive review process for new drug applications, which can often involve thousands of pages of documentation. The sudden nature of these layoffs has raised concerns about the FDA’s ability to function effectively in the future.
This significant staff reduction comes amid broader discussions about government efficiency and budget constraints. As the FDA grapples with these changes, the future of its critical work in public health remains uncertain.